Published in J Natl Cancer Inst on August 19, 2013
CYP2D6 genotyping and the use of tamoxifen in breast cancer. J Natl Cancer Inst (2013) 1.85
Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2014) 1.45
Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. J Natl Cancer Inst (2015) 1.01
Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue. Int J Mol Sci (2014) 0.84
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer. Br J Clin Pharmacol (2014) 0.81
Manganese superoxide dismutase and breast cancer recurrence: a Danish clinical registry-based case-control study, and a meta-analysis. PLoS One (2014) 0.80
Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. Br J Clin Pharmacol (2014) 0.79
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat (2015) 0.79
Genotyping concordance in DNA extracted from formalin-fixed paraffin embedded (FFPE) breast tumor and whole blood for pharmacogenetic analyses. Mol Oncol (2015) 0.79
Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues. J Mol Diagn (2015) 0.79
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat (2015) 0.78
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. J Natl Cancer Inst (2014) 0.78
CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer - a reply. Br J Clin Pharmacol (2014) 0.76
Response. J Natl Cancer Inst (2014) 0.76
Response. J Natl Cancer Inst (2014) 0.75
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity. Am J Epidemiol (2016) 0.75
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics (2002) 3.45
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol (2007) 3.36
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark. J Natl Cancer Inst (2011) 1.47
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics (2003) 1.39
Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res (2001) 1.34
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.30
Tamoxifen and CYP2D6: a contradiction of data. Oncologist (2012) 1.21
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 1.20
Chromosome 22 array-CGH profiling of breast cancer delimited minimal common regions of genomic imbalances and revealed frequent intra-tumoral genetic heterogeneity. Int J Oncol (2006) 1.09
Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue. Clin Epidemiol (2010) 1.06
Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays. Pharmacogenet Genomics (2010) 1.03
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med (2005) 28.25
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med (2003) 11.93
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst (2006) 8.38
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 7.31
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol (2013) 6.79
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell (2010) 5.57
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst (2012) 5.27
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. Nat Immunol (2005) 4.86
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther (2006) 4.81
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol (2010) 4.81
10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. Lancet (2010) 4.73
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst (2012) 4.54
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med (2010) 4.38
Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol (2013) 4.21
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med (2009) 4.16
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med (2004) 4.09
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med (2015) 4.07
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol (2010) 3.98
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol (2004) 3.87
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg (2010) 3.61
Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet (2011) 3.60
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol (2011) 3.53
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A (2010) 3.37
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
Breast cancer. Lancet (2005) 3.27
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst (2008) 3.16
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol (2008) 3.14
Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci U S A (2009) 3.10
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol (2009) 2.98
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat (2008) 2.97
NUMB controls p53 tumour suppressor activity. Nature (2008) 2.91
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell (2006) 2.87
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2006) 2.85
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82